bioRxivCancer BiologyPreprint
NPMc+ and Flt3-ITD cooperation promotes a new oncogenic HSC state that supports transformation and leukemia stem cell maintenance
Abstract
NPMc+ and FLT3-ITD are the most frequently co-occurring mutations in Acute Myeloid Leukemia (AML). Cellular and molecular mechanisms of their cooperation are largely unknown. We investigated their effects on pre-leukemic and leukemic hematopoietic stem cells (HSCs) in mouse models that recapitulate the human disease. Both oncogenes increase proliferation of pre-leukemia HSCs, however, only NPMc+ extends self-renewal, by preventing depletion of quiescent HSCs. Quiescent HSCs include dormant and active HSCs, which are dynamic and alternative phenotypic states supporting, respectively, self-renewal and regenerative haematopoiesis. Analyses of the dormant and active transcriptional programs showed that NPMc+ stimulates the dormant-to-active transition but also enforces dormancy, thus allowing dormant HSCs to be replenished. Co-expression of NPMc+ and Flt3-ITD induces a new phenotypic state of quiescent HSCs whereby dormancy and activity co-exist at single-cell level. This new state likely supports in vivo proliferation of self-renewing HSCs and rapid selection of leukemia initiating cells. Pharmacological inhibition of the TGFb cell-dormancy pathway reduces self-renewal of leukemia SCs and prolongs mouse survival allowing to conclude that enforcement of HSC dormancy is a critical determinant of unrestricted self-renewal during leukemia development and represents a target for novel anti-leukemic strategies.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dnmt3a-mutant Leukemia Stem Cells evade chemotherapy through enforced quiescence in Npm1c-Flt3ITD Acute Myeloid Leukemia
Paniz Tavakoli Shirazi, Jasmin Straube, … Steven Lane·bioRxiv·Jun 8, 2026
- PHF6 suppresses self-renewal of leukemic stem cells in AML
S. S. Jalnapurkar, A. Pawar, … V. R. Paralkar·bioRxiv·Jan 6, 2024
- Leukemia stem cell expansion cultures reveal clonal drivers of leukemogenesis and therapy response
Indranil Singh, Andrea Polazzi, … Alejo Rodriguez-Fraticelli·bioRxiv·Feb 25, 2026
- Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency
P. A. Flynn, M. D. Long, … E. F. Lind·bioRxiv·Sep 19, 2023
- FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells
Joana L. Araújo, Elvin Wagenblast, … John Edgar Dick·BloodPeer-reviewed·Jan 22, 2025
- miR-155 expression and function in leukemic stem cells
R. Garzon, C. M. Croce·bioRxiv·Feb 29, 2024